Treatment of Posterior Uveitis in Subretinal Fibrosis and Uveitis Syndrome
Subretinal fibrosis and uveitis syndrome (SFU) represents a severe and distinct form of posterior uveitis. Progressive fibrotic subretinal lesions place vision at serious and lasting risk, making appropriate management critical.
Clinical Scenario
This protocol addresses posterior uveitis in the setting of subretinal fibrosis and uveitis syndrome. While corticosteroids may offer early symptomatic benefit, progressive fibrotic subretinal lesions tend to lead to severe and permanent visual loss — underscoring the need for a more targeted approach in refractory disease.
Treatment Approach (partial overview)
Biologic therapy has been evaluated in this clinical context and has demonstrated promising outcomes in refractory cases. The complete evidence-based regimen — including agent selection and the full management sequence — is available in the structured protocol below.
References
DOI: 10.4103/0301-4738.58470
- Although steroids may benefit initially, progressive fibrotic subretinal lesions leads to severe and permanent visual loss.
- Infliximab has been tried with good results.
- Biologicals such as infliximab for the treatment of refractory non-infective posterior uveitis and severe SFU and daclizumab and tacrolimus for the treatment of BCR have been used with favorable response.